Compare Dyne Therapeutics Inc. Common Stock (DYN) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs MakeMyTrip Ltd — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while MakeMyTrip Ltd trades at $43.7 (market cap $4.21B). The key difference: MakeMyTrip Ltd is the larger of the two by market cap, and MakeMyTrip Ltd is more actively traded (954,905 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and MakeMyTrip Ltd for 12 Days on average.
| DYN | MMYT | |
|---|---|---|
Market Cap | $2.86B | $4.21B |
Volume | 3,341,579 | 954,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $90.73 |
52-Week Low | $14.60 | $36.30 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $2.18B | $4.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MakeMyTrip (MMYT) trades at $44.70, showing modest daily gains of 0.81%. The stock faces bearish technical signals with mixed earnings performance - beating Q1 2026 estimates but missing Q4 2025 and Q2 2026. Revenue growth remains positive with $978M in 2025, though profitability metrics show volatility. Analyst sentiment remains strongly bullish with a $77 consensus target representing 72% upside potential.
The stock presents significant upside based on analyst targets but faces execution risks amid volatile earnings and rising debt levels. Key catalysts include the planned Indian listing and operational resilience, while risks include geopolitical disruptions and competitive pressures in the travel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
